Polly Niravath Download Headshot

Polly Niravath, MD

  • Houston Methodist breast oncologist
  • Assistant Professor of Clinical Medicine in Oncology, Houston Methodist Institute for Academic Medicine
  • Assistant Professor of Clinical Medicine, Weill Cornell Medical College
Media Contact: Daniel Brown , 832.667.5849

Polly Niravath, MD

Request Interview
Media Contact: Daniel Brown , 832.667.5849

Areas of Expertise

  • Breast biopsy
  • Breast cancer
  • Cancer clinical trials
  • Chemotherapy
  • Pagets disease

Credentials

BOARD CERTIFICATION
Medical Oncology | University of Southern California, Los Angeles, California | 2011
Hematology | 2011
Internal Medicine | 2008
MEDICAL SCHOOL
University of California, Irvine, College of Medicine | 2005
RESIDENCY
Baylor College of Medicine - Houston, TX | 2008
FELLOWSHIP
Baylor College of Medicine - Houston, TX | 2011

Publications

HER2-positive breast cancer in patients with BRCA1/2 pathogenic variants: Case series and literature review
Munnangi, P, Niravath, PA, Chang, JC & Sun, K 2025, , Current Problems in Cancer: Case Reports, vol. 17, 100335. https://doi.org/10.1016/j.cpccr.2024.100335

Characterization of the Breast Cancer Liver Metastasis Microenvironment via Machine Learning Analysis of the Primary Tumor Microenvironment
Goodin, DA, Chau, E, Zheng, J, OConnell, C, Tiwari, A, Xu, Y, Niravath, P, Chen, SH, Godin, B & Frieboes, HB 2024, , Cancer research communications, vol. 4, no. 10, pp. 2846-2857. https://doi.org/10.1158/2767-9764.CRC-24-0263

A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Mathur, SK, Sun, K, Chang, JC, Niravath, PA, Darcourt, J, Patel, T & Teh, BS 2022, , Clinical Cancer Research, vol. 28, no. 20, pp. 4392-4401. https://doi.org/10.1158/1078-0432.CCR-22-0622

A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Sun, K, Xu, Y, Zhang, L, Niravath, P, Darcourt, J, Patel, T, Teh, BS, Farach, AM, Guerrero, C, Mathur, S, Sultenfuss, MA, Gupta, N, Schwartz, MR, Haley, SL, Nair, S, Li, X, Nguyen, TTA, Butner, JD, Ensor, J, Mejia, JA, Mei, Z, Butler, EB, Chen, SH, Bernicker, EH & Chang, JC 2022, , Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 20, pp. 4392-4401. https://doi.org/10.1158/1078-0432.CCR-22-0622, https://doi.org/10.1158/1078-0432.CCR-22-0622

Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases
Puri, A, Mylavarapu, C, Xu, J, Patel, TA, S.Teh, B, Tremont-Lukats, I, Chang, JC & Niravath, P 2022, , Breast Cancer Research and Treatment, vol. 193, no. 3, pp. 613-623. https://doi.org/10.1007/s10549-022-06595-3

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer
Chung, AW, Anand, K, Anselme, AC, Chan, AA, Gupta, N, Venta, LA, Schwartz, MR, Qian, W, Xu, Y, Zhang, L, Kuhn, J, Patel, T, Rodriguez, AA, Belcheva, A, Darcourt, J, Ensor, J, Bernicker, E, Pan, PY, Chen, SH, Lee, DJ, Niravath, PA & Chang, JC 2021, , Science translational medicine, vol. 13, no. 624, abj5070. https://doi.org/10.1126/scitranslmed.abj5070

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Anand, K, Patel, T, Niravath, P, Rodriguez, A, Darcourt, J, Belcheva, A, Boone, T, Ensor, J & Chang, J 2021, , Scientific Reports, vol. 11, no. 1, 82. https://doi.org/10.1038/s41598-020-80081-y

ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
Koca, E, Niravath, PA, Ensor, J, Patel, TA, Li, X, Hemati, P, Wong, H, Qian, W, Boone, T, Zhao, J, Ramshesh, PV, Cohen, AL, Murthy, A, Nair, S, Darcourt, JG, Belcheva, A, Kaklamani, VG & Chang, JCN 2021, , Breast Cancer Research and Treatment, vol. 188, no. 2, pp. 433-439. https://doi.org/10.1007/s10549-021-06214-7

Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy
Burns, E, Koca, E, Xu, J, McLean, E, Lee, R, Patel, T, Chang, J & Niravath, P 2021, , Oncologist, vol. 26, no. 6, pp. e936-e942. https://doi.org/10.1002/onco.13722

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
Lewis, GD, Haque, W, Farach, A, Hatch, SS, Brian Butler, E, Niravath, PA, Schwartz, MR, Bonefas, E & Teh, BS 2021, , Reports of Practical Oncology and Radiotherapy, vol. 26, no. 2, pp. 179-187. https://doi.org/10.5603/RPOR.a2021.0026



Comparison of outcomes between metaplastic and triple-negative breast cancer patients
Polamraju, P, Haque, W, Cao, K, Verma, V, Schwartz, M, Klimberg, VS, Hatch, S, Niravath, P, Butler, EB & Teh, BS 2020, , Breast, vol. 49, pp. 8-16. https://doi.org/10.1016/j.breast.2019.10.003


Omission of radiation therapy following breast conservation in older (=70 years) women with T1-2N0 triple-negative breast cancer
Haque, WM, Verma, V, Hsiao, KY, Hatch, S, Arentz, C, Szeja, S, Schwartz, M, Niravath, PA, Bonefas, E, Miltenburg, D, Butler, EB & Teh, BS 2019, , Breast Journal, vol. 25, no. 6, pp. 1126-1133. https://doi.org/10.1111/tbj.13443

Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia
Niravath, PA, Hilsenbeck, SG, Wang, T, Jiralerspong, S, Nangia, J, Pavlick, A, Ademuyiwa, F, Frith, A, Ma, C, Park, H, Rigden, C, Suresh, R, Ellis, M, Kent Osborne, C & Rimawi, MF 2019, , Breast Cancer Research and Treatment, vol. 177, no. 2, pp. 427-435. https://doi.org/10.1007/s10549-019-05319-4

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, T, Ensor, Jr. JE, Creamer, SL, Boone, T, Rodriguez, AA, Niravath, PA, Darcourt, J, Meisel, JL, Li, X, Zhao, J, Kuhn, JG, Rosato, RR, Qian, W, Belcheva, A, Schwartz, MR, Kaklamani, VG & Chang, JC 2019, , Breast Cancer Research, vol. 21, no. 1, 100. https://doi.org/10.1186/s13058-019-1186-0


TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Freedman, RA, Gelman, RS, Anders, CK, Melisko, ME, Parsons, HA, Cropp, AM, Silvestri, K, Cotter, CM, Componeschi, KP, Marte, JM, Connolly, RM, Moy, B, Van Poznak, CH, Blackwell, KL, Puhalla, SL, Jankowitz, RC, Smith, KL, Ibrahim, N, Moynihan, TJ, OSullivan, CC, Nangia, J, Niravath, PA, Tung, N, Pohlmann, PR, Burns, R, Rimawi, MF, Krop, IE, Wolff, AC, Winer, EP & Lin, NU 2019, , Journal of Clinical Oncology, vol. 37, no. 13, pp. 1081-1089. https://doi.org/10.1200/JCO.18.01511

A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes
Stubbins, R, He, T, Yu, X, Puppala, M, Ezeana, CF, Chen, S, Valdivia y Alvarado, M, Ensor, J, Rodriguez, A, Niravath, P, Chang, J, Wong, STC & Patel, T 2018, , JCO Clinical Cancer Informatics, no. 2, pp. 1-11. https://doi.org/10.1200/CCI.18.00054

Languages

  • English
  • Spanish